SAN DIEGO, Oct. 2, 2014 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage
biopharmaceutical company, announced today that Edwin L. Parsley, D.O. has joined the Company as
its Chief Medical Officer and Senior Vice President.
Dr. Parsley has been actively engaged with the Company since it
acquired Aires Pharmaceuticals, Inc. in February 2014. He has
served as Mast's interim Chief Medical Officer since September 2014 and as Chief Medical Officer of
Aires since April 2011. Dr. Parsley previously was with
Pfizer, where he oversaw clinical trials for Revatio®
(sildenafil). He is a practicing physician and certified by
the American Board of Internal Medicine in internal medicine,
pulmonary disease, critical care medicine, and sleep
medicine.
"Ed brings significant drug development and clinical expertise,
as well as over 25 years of experience treating patients with a
range of acute care needs, including patients with sickle cell
disease, heart failure and stroke in emergency department and
inpatient settings," stated Brian M.
Culley, the Company's Chief Executive Officer. "Over
the seven months since we acquired Aires, Ed has made valuable
contributions to our programs and we are delighted he has joined
our team. We believe his experience will help us achieve our
clinical and preclinical development goals over the next 12 to 18
months," Mr. Culley continued.
"I am very pleased to join Mast at this exciting time in the
Company's history," said Dr. Parsley. "With its ongoing
Phase 3 study of MST-188, Mast is a leader in a rare disease
for which there is significant unmet need and I look forward to
helping the Company achieve its goal of bringing to market the
first FDA-approved drug for sickle cell disease in over 16 years,
as well as advancing the Company's development programs in heart
failure and arterial disease."
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The
Company is leveraging the MAST (Molecular Adhesion and Sealant
Technology) platform, derived from over two decades of clinical,
nonclinical and manufacturing experience with purified and
non-purified poloxamers, to develop MST-188, its lead product
candidate, for serious or life-threatening diseases and conditions
typically characterized by impaired microvascular blood flow and
damaged cell membranes.
The Company is enrolling subjects in EPIC, a pivotal Phase 3
study of MST-188 in sickle cell disease, and in a Phase 2 study to
evaluate whether MST-188 improves the effectiveness of recombinant
tissue plasminogen activator therapy in patients with acute limb
ischemia. The Company also is planning to initiate a Phase 2
clinical study of MST-188 in patients with acute decompensated
heart failure in the first half of 2015 and to announce details of
the study's design later this year. In addition, the Company
is developing AIR001, which it acquired in February 2014, in patients with pulmonary
hypertension associated with left heart disease. More
information can be found on the Company's web site at
www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Forward Looking Statements
Mast Therapeutics cautions
you that statements included in this press release that are not a
description of historical facts are forward-looking statements that
are based on the Company's current expectations and assumptions.
Such forward-looking statements include, but are not limited to,
statements relating to Dr. Parsley's potential impact on the
Company's development programs, prospects for successful
advancement of the Company's development programs and anticipated
timing of achievement of development milestones, such as
commencement and completion of clinical and nonclinical
studies. Among the factors that could cause or contribute to
material differences between the Company's actual results and the
expectations indicated by the forward-looking statements are risks
and uncertainties that include, but are not limited to: the
uncertainty of outcomes in ongoing and future studies of the
Company's product candidates and the risk that its product
candidates, including MST-188, may not demonstrate adequate safety,
efficacy or tolerability in one or more such studies, including
EPIC; delays in the commencement or completion of clinical studies,
including as a result of difficulties in obtaining regulatory
agency agreement on clinical development plans or clinical study
design, opening trial sites, enrolling study subjects,
manufacturing sufficient quantities of clinical trial material,
being subject to a "clinical hold," and/or suspension or
termination of a clinical study, including due to patient safety
concerns or lack of funding; the potential for institutional review
boards or the FDA or other regulatory agencies to require
additional nonclinical or clinical studies prior to initiation of a
planned clinical study of a product candidate; the risk that, even
if clinical studies are successful, the FDA or other regulatory
agencies may determine they are not sufficient to support a new
drug application; the potential that, even if clinical studies of a
product candidate in one indication are successful, clinical
studies in another indication may not be successful; the Company's
reliance on contract research organizations (CROs), contract
manufacturing organizations (CMOs), and other third parties to
assist in the conduct of important aspects of development of its
product candidates, including clinical studies, manufacturing, and
regulatory activities for its product candidates, and that such
third parties may fail to perform as expected; the Company's
ability to obtain additional funding on a timely basis or on
acceptable terms, or at all; the potential for the Company to
delay, reduce or discontinue current and/or planned development
activities, including clinical studies, partner its product
candidates at inopportune times or pursue less expensive but
higher-risk and/or lower return development paths if it is unable
to raise sufficient additional capital as needed; the risk that,
even if the Company successfully develops a product candidate in
one or more indications, it may not realize commercial success with
its products and may never generate revenue sufficient to achieve
profitability; the risk that the Company is not able to adequately
protect its intellectual property rights relating to the MAST
platform and MST-188 or AIR001 and prevent competitors from
duplicating or developing equivalent versions of its product
candidates; and other risks and uncertainties more fully described
in the Company's press releases and periodic filings with the
Securities and Exchange Commission. The Company's public filings
with the Securities and Exchange Commission are available at
www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. Mast
Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof,
except as may be required by law.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
SOURCE Mast Therapeutics, Inc.